Польша -
польский -
URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)
lidocaini hydrochloridum noridem 20 mg/ml roztwór do wstrzykiwań
noridem enterprises ltd. - lidocaini hydrochloridum - roztwór do wstrzykiwań - 20 mg/ml
Европейский союз -
польский -
EMA (European Medicines Agency)
adcirca (previously tadalafil lilly)
eli lilly nederland b.v. - tadalafil - nadciśnienie tętnicze, płucne - urologiczne - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. wykazano skuteczność w idiopatycznym pah (ipah) i w pah związane z kolagenozę. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.
Европейский союз -
польский -
EMA (European Medicines Agency)
imprida hct
novartis europharm ltd. - amlodypina, walsartan, hydrochlorotiazyd - nadciśnienie - antagoniści angiotensyny ii, zwykły, antagoniści angiotensyny ii w połączeniu - leczenie samoistnego nadciśnienia tętniczego stosowania w leczeniu dorosłych pacjentów, u których ciśnienie krwi jest na połączeniu amlodypiny, walsartanu i hydrochlorotiazydu (hct), podjęte trzech pojedynczego składnika preparatów lub jako dwuskładnikowe i preparat jednoskładnikowy.
Польша -
польский -
URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)
gliclastad 30 mg tabletki o przedłużonym uwalnianiu
stada arzneimittel ag - magnesii stearas + gliclazidum - tabletki o przedłużonym uwalnianiu - 30 mg
Польша -
польский -
URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)
argadopin 300 mg tabletki
sandoz gmbh - allopurinolum - tabletki - 300 mg
Европейский союз -
польский -
EMA (European Medicines Agency)
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - zapalenie stawów, reumatoidalne - leki immunosupresyjne - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
